Skip to main content
. 2023 Feb 28;15:41. doi: 10.1186/s13195-023-01160-6

Fig. 3.

Fig. 3

A Boxplots showing the 18-month change in VOI SUVR across the quadrants. The 18-month change in VOI SUVR was significantly different between subjects in Q2 (or Q1) and Q3. B Boxplots showing the 18-month change in ADsignature VOI SUVR across the quadrants. The 18-month change in ADsignature VOI SUVR was significantly different across the quadrants (Q1 > Q2 > Q3). C Boxplots showing the 18-month change in cortical thickness across the quadrants. The 18-month change in cortical thickness was significantly different across the quadrants (Q1 < Q2 < Q3). D Boxplot showing the 18-month change in MMSE across the quadrants. The 18-month change in MMSE was significantly different across quadrants (Q1 < Q2 < Q3). A total of 109 subjects from the treatment arm of the solanezumab trial were excluded from these analyses. Note: the N’s are different in the above boxplots for flortaucipir change, thickness, and MMSE due to the availability of the data